<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733223</url>
  </required_header>
  <id_info>
    <org_study_id>2018-YXB-002</org_study_id>
    <nct_id>NCT03733223</nct_id>
  </id_info>
  <brief_title>Relationships Among FVIII, t-PA/PAI-1, and MMP-9 Levels and Intracranial Hemorrhage Complications After Thrombolysis With Alteplase in Patients With Acute Ischemic Stroke: Protocol for a Multicenter Retrospective Study</brief_title>
  <official_title>Relationships Among FVIII, t-PA/PAI-1, and MMP-9 Levels and Intracranial Hemorrhage Complications After Thrombolysis With Alteplase in Patients With Acute Ischemic Stroke: Protocol for a Multicenter Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Jinan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is to investigate the relationships among FVIII, t-PA/PAI-1,
      MMP-9 levels, and intracranial hemorrhage after thrombolysis with alteplase using a combined
      analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute ischemic stroke treated with alteplase within 4.5 hours after the onset
      of stroke symptoms will be recruited in this study. All participants will be divided into two
      groups according to whether intracranial hemorrhage occurred within 3 days after treatment
      with alteplase for analysis. Differences in FVIII, t-PA/PAI-1, and MMP-9 levels before and
      after thrombolytic therapy will be examined in both groups. This study will be conducted at
      Zhujiang Hospital of Southern Medical University, Nanfang Hospital of Southern Medical
      University, and the First Affiliated Hospital of Jinan University.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intracranial hemorrhage</measure>
    <time_frame>3 days</time_frame>
    <description>The occurrence of intracranial haemorrhage adverse reactions in ischemic stroke patients receiving thrombolytic therapy by alteplase</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <description>The patients who were treated with Ateptidase had intracranial haemorrhage adverse reactions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>The patients who were treated with Ateptidase did not have intracranial haemorrhage adverse reactions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ateptidase</intervention_name>
    <description>Treatment of ischemic stroke with Ateptidase</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ischemic stroke treated with Alteplase
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ischemic stroke and within the time window of thrombolysis (Onset of
             symptoms no more than 4.5 hours )

          -  18 y age 85 y•

          -  Symptoms of neurological deficits caused by cerebral infarction

          -  Informed consent form to confirm thrombolytic therapy have signed by patients or their
             family.

        Exclusion Criteria:

          -  A history of major head trauma or stroke in the past 3 months

          -  Suspicious subarachnoid hemorrhage

          -  Arterial puncture at noncompressible site in the last week

          -  History of intracranial hemorrhage

          -  Intracranial neoplasm, arteriovenous malformation, or aneurysm

          -  Recent intracranial or intraspinal surgery

          -  Elevated blood pressure (systolic &gt;185 mm Hg or diastolic &gt;110 mm Hg)

          -  Active internal bleeding or Acute bleeding diathesis

          -  Platelet count &lt;100×109·L-1

          -  Heparin received within 48 h resulting in aPTT above the upper limit of normal

          -  Current use of anticoagulant with INR &gt;1.7 or PT &gt;15 s

          -  Current use of thrombin inhibitors or factor Xa inhibitors

          -  Abnormal laboratory tests (eg, aPTT, INR, platelet count, ECT, TT, or appropriate
             factor Xa activity assays)

          -  Blood glucose concentration &gt; 2.7 mmol/L

          -  CT demonstrates multilobar infarction (hypodensity &gt;1/3 cerebral hemisphere)

          -  Mild cerebral infarction or rapid improvement of symptoms of cerebral infarction

          -  Symptoms of neurological impairment after seizures

          -  Major surgery or severe trauma in the past 2 weeks

          -  Gastrointestinal or urinary bleeding in the past 3 weeks

          -  History of myocardial infarction in the past 3 months

          -  Combine diseases that may affect outcomes,such as Anemia, hemophilia

          -  History of autoimmune disease or organ transplantation

          -  Pregnancy or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuai He, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Medical University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuai He, Doctor</last_name>
    <phone>862062783372</phone>
    <email>hs43555@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510280</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuai He, Doctor</last_name>
      <phone>8618520041983</phone>
      <email>hs43555@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanjaio Ma, Master</last_name>
      <phone>8618819132903</phone>
      <email>18819132903@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Wang Y, Liao X, Zhao X, Wang DZ, Wang C, Nguyen-Huynh MN, Zhou Y, Liu L, Wang X, Liu G, Li H, Wang Y; China National Stroke Registry Investigators. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke. 2011 Jun;42(6):1658-64. doi: 10.1161/STROKEAHA.110.604249. Epub 2011 Apr 21.</citation>
    <PMID>21512182</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>March 17, 2019</last_update_submitted>
  <last_update_submitted_qc>March 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>t-PA/PAI-1</keyword>
  <keyword>MMP-9</keyword>
  <keyword>FVIII</keyword>
  <keyword>Alteplase</keyword>
  <keyword>intracranial haemorrhage</keyword>
  <keyword>Ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

